Synagis Purple Book BLA 103770

BLA number
103770
Proprietary names
Synagis
Proper names
palivizumab
Applicant
Swedish Orphan Biovitrum AB (publ)
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Synagispalivizumab351(a)50MGFor InjectionIntramuscularSingle-Dose VialDiscLicensed1998-06-19
002Synagispalivizumab351(a)100MGFor InjectionIntramuscularSingle-Dose VialDiscLicensed1998-06-19
003Synagispalivizumab351(a)50MG/0.5MLInjectionIntramuscularSingle-Dose VialRxLicensed2004-07-23
004Synagispalivizumab351(a)100MG/1MLInjectionIntramuscularSingle-Dose VialRxLicensed2004-07-23

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2020-11-01U001Synagis351(a)DiscSwedish Orphan Biovitrum AB (publ)
2020-11-01U002Synagis351(a)DiscSwedish Orphan Biovitrum AB (publ)
2020-11-01U003Synagis351(a)RxSwedish Orphan Biovitrum AB (publ)
2020-11-01U004Synagis351(a)RxSwedish Orphan Biovitrum AB (publ)
2020-05-01R001Synagis351(a)DiscMedImmune, LLC
2020-05-01R002Synagis351(a)DiscMedImmune, LLC
2020-05-01R003Synagis351(a)RxMedImmune, LLC
2020-05-01R004Synagis351(a)RxMedImmune, LLC

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-05-01001Synagis351(a)DiscLicensed1998-06-19
2020-05-01002Synagis351(a)DiscLicensed1998-06-19
2020-05-01003Synagis351(a)RxLicensed2004-07-23
2020-05-01004Synagis351(a)RxLicensed2004-07-23